Carly Helfand on Muck Rack

Carly Helfand

Washington, D.C.
Reporter and Editor — Fierce Pharma

Reporter/editor for @FiercePharma and FiercePharmaMarketing; Chicago native; intent traveler; hockey fan; Irish fiddler; comma police.

Search Tweets

Twitter Feed

@CarlyHFierce — 2,206 followers, 4,058 tweets

Sep 14, 2017

Why did AstraZeneca's Bydureon fail to cut CV risks? A broad patient group, perhaps:  $AZN #EASD2017 #pharma

Sep 14, 2017

#ICYMI at #EASD17 - BI, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point  $LLY #pharma

Sep 14, 2017

#EASD2017 : AstraZeneca's Farxiga cuts HbA1c, weight and insulin use in Type 1 study  $AZN #pharma

Show more